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Abstract 
AIM: To compare the effectiveness of narrowband ultraviolet B (NBUVB) and oral methotrexate (MTX) to oral 
MTX alone in Vietnamese psoriasis patients, from May 2016 to May 2018.  
METHODS: We conducted a non-randomized trial on 70 patients with plaque-type psoriasis of moderate to 
severe. Thirty-five patients apply NBUVB once/day in 5 days/week for 4 weeks plus oral MTX 7.5 mg/week and 
35 patients oral MTX 7.5 mg/week and both two groups treatment for 3 months. The extent of the lesion was 
assessed by the Psoriasis Area and Severity Index (PASI).  
RESULTS: The proportion of decreasing PASI was comparable (68.49% in NBUVB and MTX versus 57.62% in 
MTX alone); p < 0.05. Inside, good 28.58%, moderate 68.57% and poor 2.85% in NBUVB and MTX better than 
good 2.85%, moderate 71.4% and poor 25.72% in MTX alone; p < 0.05. The recurrence rate after 24 months of 
the NBUVB and MTX group (42.9%) was lower than the MTX alone group (71.4%); p < 0.05.  
CONCLUSION: NBUVB and oral MTX have affected treatment with chronic plaque psoriasis better than oral MTX 
alone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Psoriasis is a chronic skin disease. It happens 
to every gender, age and race develops in 1-3% world 
population [1]. The pathology of this disease is not 
fully understood. Until now, most authors consider it 
has a genetic base and autoimmune mechanism 
started with psychological distress, environment, 
infection, where Th17 and Th1 play a key role [2]. 
There are many methods and drugs used to treat 
psoriasis: topical ones, such as coal tar, salicylic, 
corticoid; systemic therapies like MTX, cyclosporine 
and biological drugs. 
Narrowband ultraviolet B (NBUVB) have 
shown effectiveness in psoriasis treatment, few side 
effects, children tolerance and inexpensiveness. The 
result will be more promising if we combine the 
therapy with retinoid or MTX. 
In Vietnam, the psoriasis treatment with 
NBUVB (UVB-311nm) in combination with low dose 
MTX has not been studied or reported. Because of 
this reason, our research evaluates the efficacy of this 
combination therapy. 
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Material and Methods 
 
Study design 
We conducted a non-randomized controlled 
trial on adults with chronic plaque-type psoriasis, from 
moderate to severe.  
Including criteria: Patients with Fitzpatrick skin 
photo-types III and IV, age > 16 with no 
contraindication for UVB and MTX.  
Excluding criteria: mild psoriasis and patients 
with contraindication for UVB and MTX. 
Sample size: according to the formula of 
World Health Organization: 
 n1 = n2 = {[Z1-a/2Ö[2P(1 - P) + ZbÖP1(1 - P1) + 
P2(1 - P2)]}
2 
/ (P1 - P2)
2
 
n1: Sample size of experimental group 1; n2: 
Sample size of control group 2 
Z1-a/2: reliability coefficient 95% (= 1,96); Zb: 
validity (= 1,645) 
P1: percentage of good patients in NBUVB 
plus MTX group: estimation from previous studies was 
85% (0.85); P2: percentage of good patients in MTX 
alone: estimation from previous studies w as 55%. P = 
P1 + P2/2. Sample size of group 2 (n1 = n2) = 30 
patients.  
 
Treatment procedure  
NBUVB and MTX group: Initial UVB dose was 
500 mJ, increased after each treatment of 100 mJ 
until reaching minimal erythema dose or maximum 
dose, which was 2000 mJ. Lighted once a day, 5 
consecutive days/week (from Monday to Friday) in 
association with methotrexate 7.5 mg/week on a fixed 
day, after dinner and phisiogel, twice a day, for four 
weeks. MTX alone group: Methotrexate 7.5 mg/week 
on a fixed day, after dinner and phisiogel twice a day 
for four weeks.  
Both groups were treated for 4 weeks 
according to the study's guideline. After discharging 
both two groups continued oral MTX 7.5 mg/week 
until week 12. Monitoring for recurrence after 16 
weeks and 24 weeks.  
 
Applied techniques 
To evaluate the disease activity according to 
PASI [3] PASI = 0,1(EH + IH + DH)AH + 0,2(EU + IU + 
DU)AU + 0,3(ET + IT + DT)AT + 0,4(EL + IL + DL)AL 
Level :3 levels according to PASI: mild PASI: 
< 10, moderate: PASI: < 20, severe: PASI: ≥ 20. 
Evaluating the outcome: clinical improvement was 
evaluated through percentage decrease of PASI by 
using this formula:  
 % PASI = PASI before treatment-PASI after 
treatment/ PASI before treatment x 100 
5 levels: very good: PASI decreases 100%; 
good: PASI decreases 75% - 99%; fair: PASI 
decreases 50 % ≤ 75%; moderate: PASI decreases 
25% ≤ 50% and poor: PASI decreases < 25%. 
 
 
Results 
 
We recruited 35 patients from May 2016 to 
May 2018, to the NBUVB and MTX group and 35 to 
the oral MTX alone. Table 1 shows the baseline 
characteristics of the two groups, with no significant 
difference. 
Table 1: Comparing the characteristics of the 2 groups. Note: 
the characteristics of 2 groups was similar, p > 0.05 
Index Experimental group Control group P 
Mean age 51.46 ± 8.9 52.03 ± 9.3 > 0.05 
Gender: male/female 30/5 30/5 > 0.05 
Disease activity: 
moderate/severe 
23/12 27/8 > 0.05 
 
The treatment outcome of NBUVB and MTX 
group shows the proportion of decreasing PASI 
68,49%, better than MTX alone (57.62%); p < 0.05 as 
shown in Table 2.  
Table 2: Comparing the general outcome of 2 groups 
Group n PASI before 
treatment 
PASI after 4 
weeks of 
treatment 
PASI decrease 
Number % 
NBUVB + MTX group 35 17.39 ± 6.3 5.48 ± 2.6 11.91 68.49 
MTX alone group 35 16.66 ± 5.2 7.06 ± 2.8 9.6 57.62 
p < 0.05 
Note: The treatment outcome of NBUVB plus MTX group was better than MTX alone 
group, with p < 0.05. 
 
The treatment outcome of experimental group 
and control group was 88.57% and 74.28% 
respectively, p < 0.05. Inside, good 28.58%, moderate 
68.57% and poor 2.85% in NBUVB and MTX better 
than good 2.85%, moderate 71.4% and poor 25.72% 
in MTX alone; p < 0.05 as shown in Table 3.  
Table 3: Comparing the treatment outcome according to the 
evaluation levels of 2 groups 
Result NBUVB + MTX group MTX alone group p 
Very good 0 0  
 
< 0.05 
Good 10/35 (28.58%) 1/35 (2.85%) 
Moderate 24/35 (68.57%) 25/35 (71.43%) 
Poor  1/35 (2.85%) 9/35 (25.72%) 
Total 35 (100%) 35 (100%) 
Note: The treatment outcome which was evaluated as good and moderate of NBUVB plus 
MTX group and MTX alone group was 88.57% and 74.28% respectively, p < 0.05. 
 
The recurrence rate after 24 months of the 
NBUVB and MTX group (42.9%) was lower than the 
MTX alone group (71.4%); p < 0.05. The side effects 
of 2 groups: Red blood cells, white blood cells, 
platelets, AST, ALT, urea, creatinine of 2 groups 
before treatment and after treatment 4 weeks were in 
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normal range. 5 patients in the experimental group 
referred a headache: 2 nausea, 2 erythema while in 
the MTX alone group: 3 nausea, 3 a headache. No 
patients had to discontinue treatment because of 
these side effects.  
 
 
Discussion 
 
According to Table 2, the experimental group 
showed PASI decreased 68.82% from 17.39 to 5.48 
after 4 weeks treatment in hospital. Methotrexate 
alone group, PASI decreased 57.62% from 16.66 to 
7.06 after 4 weeks. In conclusion, both groups had 
treatment efficacy, but NBUVB and MTX group were 
better than the control group, p < 0.05. Combined 
NBUVB and methotrexate were more promising than 
methotrexate alone in psoriasis treatment, but 
recurrence after 3 months, 6 months of 2 groups was 
not different [4]. Our study outcome was similar to 
Soliman et al. research, demonstrating that 
methotrexate and NBUVB are superior to 
methotrexate alone.  
In Mahajan et al., study (2010) experimental 
group achieved PASI-75 faster than the control group, 
which used only UVB and placebo [5]. In conclusion, 
Mahajan’s study result was not different from our 
research showing that the combination is more 
effective than NBUVB or methotrexate alone. 
According to Wolf et al., (2012), a combination of 
NBUVB and ustekinumab showed a better result than 
ustekinumab alone [6], and NBUVB with adalimumab 
demonstrated the same result [7]. According to Paul 
et al-1982, methotrexate plus UVB for 26 psoriasis 
vulgaris patients cleared lesions faster and decreased 
the dose of both methotrexate and UVB [8].  
Evaluating the clearance of lesions or PASI 
decrease, table 3 showed that NBUVB and low dose 
methotrexate group and methotrexate alone group 
had good (28.58% and 2.85%), moderate (68.57% 
and 71.43%) and poor (2.85% and 25.72%) result, 
respectively. In conclusion, NBUVB plus MTX group 
had a better response than MTX alone group, p < 
0.05. We think this result is suitable for the indication 
of these drugs. Moreover, in clinical practice, we used 
NBUVB for mild and moderate patients achieving 
good results. So moderate and severe patients used 
methotrexate even low dose can still acquire good 
response because both treatments inhibit interferon 
gamma and Th17 [9], [10], [11]. 
After four weeks treatment, the mean value of 
tests involving hematopoietic function (red blood cells, 
white blood cells, platelets), liver function (AST, ALT), 
kidney function (urea, creatinine) of both groups 
before and after treatment, were in normal range. Side 
effects included nausea, headache, erythema and 
pruritus happened in a few patients, and no one had 
to stop the treatment.  
The recurrence rate after 24 weeks of the 
control group was 71.4% higher than the experimental 
group (42.9%). This difference had statistical 
significance with p < 0.01. These results showed that 
NBUVB plus methotrexate has not only better efficacy 
but also longer disease stability than methotrexate 
only. In literature, NBUVB is effective in psoriasis and 
had few side effects and can use for both children and 
pregnancy.  
In conclusion, NBUVB and oral MTX have 
affected treatment better than oral MTX alone with 
chronic plaque psoriasis in Vietnam.  
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